Ocugen OCGN is building its ocular portfolio around a modifier gene therapy idea: instead of designing a therapy for a single genetic defect, the platform is intended to work across many underlying ...

Age-related macular degeneration (AMD) is the leading cause of blindness in the West. Delays in injections can cause ...

General practitioners must screen for ocular mpox and refer to ophthalmology urgently to prevent severe vision-threatening complications.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Current treatments for corneal neovascularization rely on invasive intravitreal injections, which limit patient compliance and carry significant risks. To address this, researchers developed a ...

Intraocular inflammation following high dose aflibercept may be more common in practice than phase 3 trials found.

Full-year 2025 net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI® ...

Vermont needs to strengthen rural health care, reduce costs, and increase access; S.64 does just that. Optometrists — after earning a rigorous advanced procedures specialty license — would be able to ...

First ever successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment Superiority primary endpoint met with 74.1% ...